SCTX — Scribe Therapeutics Share Price
Last trade - 00:00- $330.17m
- $445.31m
- $51.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -92.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 27.41 | 51.17 | 11.56 | 6.73 | 86.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. It focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The Company's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 30th, 2017
- Public Since
- July 24th, 2026
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 18,931,680
- Address
- 1150 Marina Village Pkwy, ALAMEDA, 94501
- Web
- https://www.scribetx.com
- Phone
- +1 9086427374
- Auditors
- Deloitte & Touche LLP
Similar to SCTX
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
As of Today at 04:11 UTC, shares in Scribe Therapeutics are trading at $17.44. This share price information is delayed by 15 minutes.
Shares in Scribe Therapeutics last closed at $17.44 and the price had moved by over the past 365 days. In terms of relative price strength the Scribe Therapeutics share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for Scribe Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreScribe Therapeutics does not currently pay a dividend.
Scribe Therapeutics does not currently pay a dividend.
Scribe Therapeutics does not currently pay a dividend.
To buy shares in Scribe Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $17.44, shares in Scribe Therapeutics had a market capitalisation of $330.17m.
Here are the trading details for Scribe Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SCTX
Based on an overall assessment of its quality, value and momentum Scribe Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Scribe Therapeutics is $57.00. That is 226.83% above the last closing price of $17.44.
Analysts covering Scribe Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.87 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scribe Therapeutics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $17.44, shares in Scribe Therapeutics were trading -27.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scribe Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Scribe Therapeutics' directors